3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
157
Carcinoma, Transitional Cell
56
Non-Muscle Invasive Bladder Neoplasms
30
Urethral Neoplasms
24
Carcinoma, Renal Cell
23
Neoplasms
19
Kidney Neoplasms
15
Pancreatic Neoplasms
14
Ovarian Neoplasms
14
Neoplasm Metastasis
13
Carcinoma, Non-Small-Cell Lung
13
Prostatic Neoplasms
12
Ureteral Neoplasms
11
Urologic Neoplasms
9
Colorectal Neoplasms
9
Breast Neoplasms
9
Lung Neoplasms
7
Testicular Neoplasms
6
Stomach Neoplasms
6
Melanoma
6
Sarcoma
5
Urothelial Cancer
4
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Osteosarcoma
4
Colonic Neoplasms
4
Urogenital Neoplasms
3
Triple Negative Breast Neoplasms
3
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Interventions
fluciclovine F-18
2
relatlimab
1
pembrolizumab
1
enfortumab vedotin
1
darolutamide
1
Radiation Dose Hypofractionation
1
Nivolumab
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Diseases
×
Gemcitabine
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled